WEST PHARMACEUTICAL SERVICES INC reported revenue of $0.87B for the period ended 2026-06-30, +13.8% year on year. Net income was $0.15B, a 17.7% net margin on a 37.7% gross margin. The largest revenue line is Proprietary Products at 83% of the total. Free cash flow for the period was $0.08B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.87B | +13.8% |
| Gross profit | $0.33B | — |
| Operating income | $0.18B | — |
| Net income | $0.15B | +16.8% |
| Gross margin | 37.7% | Net margin 17.7% |
| Revenue Q/Q | +3.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| Proprietary Products | $0.72B | 82.8% |
| West Vantage | $0.15B | 17.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.54B | 62.3% |
| R&D | $0.02B | 2.3% |
| SG&A | $0.12B | 13.5% |
| Tax & other | $0.03B | 2.9% |
| Item | Amount |
|---|---|
| Total assets | $4.08B |
| Total liabilities | $1.09B |
| Shareholders' equity | $2.99B |
| Equity / assets | 73.4% |
| Operating cash flow | $0.12B |
| Capital expenditure | $0.04B |
| Free cash flow | $0.08B |
| Cash conversion (OCF / net income) | 81% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
WDC ・ WY ・ WSM ・ WMB ・ WTW ・ WDAY ・ WYNN ・ XEL ・ XYL ・ YUM ・ ZBRA ・ ZBH
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies